

FOR MORE INFORMATION:

Bob Kneeley
Director, Investor Relations
954-384-0175, x-5300
bob_kneeley@pediatrix.com

FOR IMMEDIATE RELEASE

**Pediatrix Screening Enters License Agreements
With Private Labs Serving Spain, Portugal, Western U.S.**

FORT LAUDERDALE, FLORIDA, October 19, 2005 – Pediatrix™ Screening, Inc., a Pediatrix Medical Group, Inc., company and one of the world's largest providers of newborn metabolic screening services, has expanded the availability of its proprietary services by entering into license agreements with a private laboratory in Spain and by renewing and expanding an existing license agreement with ARUP Laboratories, a reference laboratory based in Salt Lake City, Utah.

Laboratorio de análisis Dr. Echevarne has licensed Pediatrix Screening's European patent-pending technology to provide newborn metabolic screening services to babies born in Spain and Portugal. The agreement is for 10 years and is exclusive for Spain. Specific terms were not disclosed. In 2004, there were approximately 480,000 live births in Spain and Portugal combined, according to the World Health Organization.

Pediatrix Screening also renewed its existing license agreement with Associated Regional and University Pathologists, Inc. (ARUP Laboratories) for a 10-year period. ARUP retains exclusive rights to Pediatrix Screening's technology to perform comprehensive newborn metabolic screening for all babies born in Utah. ARUP also has acquired non-exclusive rights to provide newborn metabolic screening for babies born in Arizona, Montana and New Mexico. There were approximately 180,000 babies born in those four states annually.

Pediatrix Screening's proprietary technology provides a method for genetic screening of newborns through tandem mass spectrometry, as well as interprets results of newborn screening through tandem mass spectrometry.

Pediatrix Screening is actively pursuing distributor and licensing opportunities to make it possible to detect treatable metabolic disorders through comprehensive newborn screening to babies born throughout the world. In March 2005, IVAX Corporation entered into a strategic alliance to distribute Pediatrix Screening's StepOne™ Newborn Screening Program throughout Latin America.

Pediatrix Screening's patents to use tandem mass technology for newborn screening make it possible to detect a broad panel of potentially devastating metabolic

disorders that, when caught early, are easily treated or prevented. Through a combination of tandem mass spectrometry, molecular and biochemical testing, Pediatrix Screening offers a comprehensive screening tool that can detect the presence of up to 50 metabolic disorders.

About Pediatrix

Pediatrix was founded in 1979. Pediatrix physicians and advanced nurse practitioners are reshaping the delivery of maternal-fetal and newborn care, identifying best demonstrated processes and participating in clinical research to enhance patient outcomes and provide high-quality, cost-effective care. Its neonatal physicians provide services at more than 220 NICUs, and through Obstetrix, its perinatal physicians provide services in many markets where Pediatrix's neonatal physicians practice. Combined, Pediatrix and its affiliated professional corporations employ more than 800 physicians in 32 states and Puerto Rico. Pediatrix is also the nation's largest provider of newborn hearing screens and newborn metabolic screening. Additional information is available at www.pediatrix.com.

About Laboratorio de análisis Dr. Echevarne

Laboratorio de análisis Dr. Echevarne was founded in 1958 and is headquartered in Barcelona with a presence in all major cities throughout Spain and Portugal, as well as its management of 18 hospital-based laboratories. In 2004, the laboratory performed 16 million tests in its clinical department only. The laboratory is currently processing samples from 6,000 patients on a daily basis. Constant technical improvements and customer adaptability have made the laboratory one of the most advanced in Europe. Echevarne currently employs over 700 professionals at a total of 46 laboratory facilities. Research and specialized training activities are carried out by the Echevarne Foundation, a non-profit making institution, established in 1993 to promote both basic and applied research in analytical medicine, with a strong interest in molecular pathologies. Additional information is available at www.echevarne.com.

About ARUP

ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and an enterprise of the University of Utah and its Department of Pathology. With nearly 1,800 employees, ARUP offers in excess of 2,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays, for patients throughout the United States. Rather than competing with its clients for physician office business, ARUP chooses instead to support clients' existing test menus by offering highly complex and unique tests, with accompanying consultative support, to enhance their abilities to provide local and regional laboratory services. ARUP's clients include more than half of the nation's university teaching hospitals and children's hospitals, as well as multi-hospital groups, major commercial laboratories,

group purchasing organizations, military and government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology™. For more information about ARUP Laboratories, visit www.aruplab.com.

#

Certain statements and information in this press release may be deemed to be “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe”, “hope”, “may”, “anticipate”, “should”, “intend”, “plan”, “will”, “expect”, “estimate”, “project”, “positioned”, “strategy” and similar expressions, and are based on assumptions and assessments made by Pediatrix’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and Pediatrix undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in Pediatrix’s most recent Annual Report on Form 10-K, including the section entitled “Risk Factors”.